Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05946213 · ClinicalTrials.gov registry record · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
A Phase 3 study of Prostate Adenocarcinoma and Stage III Prostate Cancer AJCC v8, sponsored by NRG Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,209
- Enrollment target
- 20
- Study locations
NCT05946213: Recruiting Phase 3 study of Prostate Adenocarcinoma and Stage III Prostate Cancer AJCC v8, sponsored by NRG Oncology.
NCT05946213 is a Phase 3 study of Prostate Adenocarcinoma and Stage III Prostate Cancer AJCC v8 that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 1,209 participants, above the 206-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (487% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05946213, a Phase 3 study of Prostate Adenocarcinoma and Stage III Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by NRG Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,209 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Primary Outcome
Based on conventional imaging. Median MFS time comparing the curves.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- RADIATION External Beam Radiation Therapy
- PROCEDURE Bone Scan
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Tower Cancer Research Foundation - Beverly Hills
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fremont - Fremont
- Washington Hospital - Fremont
- Fresno Cancer Center - Fresno
- Kaiser Permanente Fresno Orchard Plaza - Fresno
- Kaiser Permanente-Fresno - Fresno
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- Cedars Sinai Medical Center - Los Angeles
- Kaiser Permanente- Modesto MOB II - Modesto
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente Oakland-Broadway - Oakland
- Kaiser Permanente-Oakland - Oakland
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Kaiser Permanente-Rancho Cordova Cancer Center - Rancho Cordova
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
- The Kirklin Clinic at Acton Road - Birmingham
- Lewis and Faye Manderson Cancer Center - Tuscaloosa
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,209 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2036-03-31 |
| Phase | Phase 3 |
What NCT05946213 shows while recruiting
NCT05946213 is an interventional study that assigns participants to a tested intervention. Its 1,209 participants enrollment target places it among the larger protocols in the corpus, above the 206-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (487% higher).
The record links to 3 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05946213 names 20 study sites across 3 states, led by California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05946213 about?
NCT05946213 is a clinical study titled "Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer". This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a pa...
What is the current status of trial NCT05946213?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,209 participants. The study started on 2023-12-14. Estimated completion is 2036-03-31.
What conditions does trial NCT05946213 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8.
What interventions are being tested in trial NCT05946213?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), External Beam Radiation Therapy (RADIATION), Bone Scan (PROCEDURE).
Who is sponsoring clinical trial NCT05946213?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05946213 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05946213's enrollment target sits among peer trials
1,209 3rd of 99 higher than 97 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
RECRUITING · Phase 3
-
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RECRUITING · Phase 3
-
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
RECRUITING · Phase 3
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
- NCT07038785 · 1,204 participants
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI